

Meyaard Daniel V  
 Form 4  
 February 19, 2013

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Meyaard Daniel V

2. Issuer Name and Ticker or Trading Symbol  
 IDEXX LABORATORIES INC /DE [IDXX]

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)

(Last) (First) (Middle)  
 ONE IDEXX DRIVE  
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)  
 02/14/2013

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 Officer (give title below) \_\_\_\_\_ Other (specify below)  
 Corporate Vice President

WESTBROOK, ME 04092  
 (City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 \_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) |        | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|--------|---|--|-----------------------------------|
|                                 |                                      |  |                                | (A) or (D)                                    | Price  |   |  |                                   |
| Common Stock                    | 02/14/2013                           |  | M                              | 143   | A \$ 0 | 4,255 <sup>(1)</sup>  | D  |                                   |
| Common Stock                    | 02/14/2013                           |  | M                              | 161   | A \$ 0 | 4,416   | D  |                                   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Security (Instr. 3 and 4) | Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|----------------------------|
| Non-Qualified Stock Option (right to buy)  | \$ 91.68   | 02/14/2013                           |  | A                              | 5,964   | <u>(2)</u> 02/13/2020                                    | Common Stock  | 5,964                      |
| Incentive Stock Option (right to buy)      | \$ 91.68   | 02/14/2013                           |  | A                              | 1,090   | <u>(3)</u> 02/13/2020                                    | Common Stock  | 1,090                      |
| Restricted Stock Unit                      | <u>(4)</u>   | 02/14/2013                           |  | A                              | 682   | <u>(4)</u> <u>(4)</u>                                    | Common Stock  | 682                        |
| Restricted Stock Unit                      | <u>(5)</u>   | 02/14/2013                           |  | M                              | 143   | <u>(5)</u> <u>(5)</u>                                    | Common Stock  | 143                        |
| Restricted Stock Unit                      | <u>(6)</u>   | 02/14/2013                           |  | M                              | 161   | <u>(6)</u> <u>(6)</u>                                    | Common Stock  | 161                        |

## Reporting Owners

| Reporting Owner Name / Address                             | Relationships |           |                          |       |
|--|---------------|-----------|--------------------------|-------|
|  | Director      | 10% Owner | Officer                  | Other |
| Meyaard Daniel V<br>ONE IDEXX DRIVE<br>WESTBROOK, ME 04092 |               |           | Corporate Vice President |       |

## Signatures

Conan R. Deady, Attorney-in-Fact for Daniel V. Meyaard  
Date: 02/19/2013

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Includes 41 shares and 51 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on 09/30/2012 and 12/31/2012, respectively.

(2)

## Edgar Filing: Meyaard Daniel V - Form 4

Grant of options to buy shares of common stock becomes exercisable as to 1,411 shares on 02/14/2014, 02/14/2015, 02/14/2016 and 02/14/2017, and the remaining 320 shares on 02/14/2018.

- (3) Grant of options to buy shares of common stock that vest on the fifth anniversary date (02/14/2018) of the grant.
- (4) Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary date (02/14/2014) of the date of grant.
- (5) Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary date (02/14/2013) of the date of grant.
- (6) Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary date (02/14/2012) of the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.